chlorthalidone has been researched along with Atherosclerosis in 2 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 7.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 3.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clezar, CN | 1 |
| Flumignan, CD | 1 |
| Cassola, N | 1 |
| Nakano, LC | 1 |
| Trevisani, VF | 1 |
| Flumignan, RL | 1 |
| Black, HR | 1 |
| Davis, B | 1 |
| Barzilay, J | 1 |
| Nwachuku, C | 1 |
| Baimbridge, C | 1 |
| Marginean, H | 1 |
| Wright, JT | 1 |
| Basile, J | 1 |
| Wong, ND | 1 |
| Whelton, P | 1 |
| Dart, RA | 1 |
| Thadani, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for chlorthalidone and Atherosclerosis
| Article | Year |
|---|---|
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
1 other study available for chlorthalidone and Atherosclerosis
| Article | Year |
|---|---|
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S | 2008 |